The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...